See All Slides - tctmd.com

Slides

Presentation TCT 2022

How Important Is Complete Revascularization?

Presenter: Megha Prasad

September 18, 2022

Presentation TCT 2022

Outcomes of Mitral Regurgitation Patients Screen Failed for LVOT Obstruction Treated Using Altavalve

Presenter: Vinayak N. Bapat

September 18, 2022

Presentation TCT 2022

TCT 671: A Rare Complication During TAVI. Valve (and STENT) for Life.

Presenter: Christan Roguelov

September 18, 2022

The Dedicated JenaValve TAVR System for AI: Early EU and US Experiences

Presentation TCT 2022

The Dedicated JenaValve TAVR System for AI: Early EU Experience

Presenter: Alexander Tamm

September 18, 2022

Presentation TCT 2022

TCT 133: Efficacy and Safety of Drug-coated Balloons According to Coronary Vessel Size. A Report from the BASKET-SMALL 2 Trial

Presenter: Bruno Scheller

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

TCT 339: Less invasive Ventricular Enhancement (LIVE) procedure for the treatment of ischaemic heart disease - short and medium term outcomes

Presenter: Azfar Zaman

September 18, 2022

Presentation TCT 2022

For Most Patients, Only Spontaneous MI Is Relevant

Presenter: Alexandra J. Lansky

September 18, 2022

Presentation TCT 2022

Transfemoral TMVR: Intermediate-Term Outcomes From the Intrepid Early Feasibility Study

Presenter: Firas Zahr

September 18, 2022

Presentation TCT 2022

Tips and Tricks with Workhorse TAVR Devices

Presenter: Raj Makkar

September 18, 2022

Advertisement

Slides

How Important Is Complete Revascularization?

Outcomes of Mitral Regurgitation Patients Screen Failed for LVOT Obstruction Treated Using Altavalve

TCT 671: A Rare Complication During TAVI. Valve (and STENT) for Life.

The Dedicated JenaValve TAVR System for AI: Early EU Experience

TCT 133: Efficacy and Safety of Drug-coated Balloons According to Coronary Vessel Size. A Report from the BASKET-SMALL 2 Trial

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

TCT 339: Less invasive Ventricular Enhancement (LIVE) procedure for the treatment of ischaemic heart disease - short and medium term outcomes

For Most Patients, Only Spontaneous MI Is Relevant

Transfemoral TMVR: Intermediate-Term Outcomes From the Intrepid Early Feasibility Study

Tips and Tricks with Workhorse TAVR Devices

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content